Results 151 to 160 of about 405,087 (261)

1166. Helianthus occidentalis Riddell

open access: yesCurtis's Botanical Magazine, EarlyView.
Summary Helianthus occidentalis Riddell (Compositae: Heliantheae: Helianthinae) is described and illustrated. The species' placement in the genus is commented on, as are the differences in infrageneric placement of the other species Heiser originally grouped H. occidentalis with.
Nicholas Hind, Christabel King
wiley   +1 more source

From the Field to the Laboratory: The Theory‐Practice Research of Peter J. Carnevale

open access: yesNegotiation and Conflict Management Research, EarlyView., 2020
Abstract As colleagues and collaborators, we reflect on the work and legacy of Peter Carnevale, currently professor at the University of Southern California, and recipient of the 2002 Jeffrey Z. Rubin Theory‐to‐Practice Award of the International Association for Conflict Management (IACM). We review Carnevale’s main contributions, including his work on
Linda L. Putnam   +3 more
wiley   +1 more source

Isolated ascending colon perforation from blunt trauma in an eleven-year-old adolescent: a case report. [PDF]

open access: yesBMC Surg
Al-Slaibi I   +8 more
europepmc   +1 more source

Evidence‐ and consensus‐based guideline on lichen sclerosus

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The German‐language, consensus‐ and evidence‐based S3 guideline on lichen sclerosus (LS) was developed based on the European “EuroGuiDerm Guideline on lichen sclerosus” under the leadership of the German Dermatological Society (DDG) and the German Society for Gynecology and Obstetrics (DGGG).
Gudula Kirtschig   +25 more
wiley   +1 more source

Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) remains the most common aggressive lymphoma, representing a biologically heterogeneous disease with diverse clinical behaviors. For more than two decades, R‐CHOP has been the cornerstone of frontline treatment, curing approximately two‐thirds of patients.
Mamdouh Skafi   +12 more
wiley   +1 more source

Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM

open access: yesEuropean Journal of Haematology, EarlyView.
The graphical abstract illustrates the mechanism of action of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting cereblon‐mediated degradation of IKZF1 and IKZF3. Compared with classical immunomodulatory drugs (IMiDs), CELMoDs induce deeper IKZF1/3 depletion, leading to more pronounced suppression of the IRF4–MYC survival axis ...
Maria Eugenia Alvaro   +12 more
wiley   +1 more source

Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Primary refractory Diffuse Large B‐Cell Lymphoma is associated with poor outcomes and limited responsiveness to conventional salvage therapies. Although CAR T‐cell therapy represents the standard of care in this setting, a substantial proportion of patients cannot receive it despite meeting disease‐related criteria. In this review, “unsuitable”
Santino Caserta   +12 more
wiley   +1 more source

Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Relapsed and refractory multiple myeloma (RRMM) remains associated with poor outcomes, particularly in patients exposed or refractory to proteasome inhibitors, immunomodulatory agents, and anti‐CD38 monoclonal antibodies. Targeting B‐cell maturation antigen (BCMA) has emerged as an effective therapeutic strategy, prompting the development of ...
Maria Eugenia Alvaro   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy